| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CCNB1; CCNB; G2/mitotic-specific cyclin-B1 |
| Entrez GeneID | 891 |
| WB Predicted band size | Calculated MW: 48 kDa; Observed MW: 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Cyclin B1. AA range:91-140 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于Cyclin B1抗体的3篇代表性文献，涵盖其应用及机制研究：
---
1. **文献名称**：*Cyclin B1 expression in colorectal cancer and its relationship with prognosis*
**作者**：Yang, L., Liu, F., Tong, G.
**摘要**：本研究通过免疫组化(IHC)和Western blot分析结直肠癌组织中Cyclin B1的表达水平，发现其高表达与肿瘤进展和不良预后显著相关。研究验证了所用抗体的特异性，并表明Cyclin B1可能作为潜在的预后生物标志物。
2. **文献名称**：*Cell cycle-regulated phosphorylation of Cyclin B1: Antibody-based detection in synchronized cells*
**作者**：Jackman, M., Lindon, C., Pines, J.
**摘要**：文章开发了一种特异性识别磷酸化Cyclin B1的抗体，用于研究细胞周期同步化过程中Cyclin B1的磷酸化动态变化。通过流式细胞术和免疫印迹，揭示了其在G2/M期调控中的关键作用。
3. **文献名称**：*Cyclin B1 overexpression enhances radiation sensitivity in breast cancer cells: Role of antibody-targeted therapy*
**作者**：Dai, W., Cogswell, J.P.
**摘要**：研究利用抗Cyclin B1抗体筛选乳腺癌细胞系，发现Cyclin B1高表达与放疗敏感性增加相关。通过siRNA和抗体阻断实验，证实其调控DNA损伤修复通路，提示靶向Cyclin B1的治疗潜力。
---
**备注**：上述文献为领域内典型研究方向示例，具体发表信息需通过数据库(如PubMed)检索确认。若需实际引用，建议使用关键词“Cyclin B1 antibody”结合研究主题进一步筛选。
Cyclin B1. a key regulatory protein in the cell cycle, plays a critical role in controlling the transition from the G2 phase to mitosis (M phase). It forms a complex with cyclin-dependent kinase 1 (CDK1), activating its kinase activity to drive mitotic entry by phosphorylating substrates involved in nuclear envelope breakdown, chromatin condensation, and spindle assembly. Cyclin B1 expression fluctuates during the cell cycle, peaking during G2/M before undergoing rapid degradation via the ubiquitin-proteasome system during mitosis. Dysregulation of Cyclin B1 is linked to genomic instability and tumorigenesis, with overexpression observed in various cancers, making it a potential biomarker or therapeutic target.
Antibodies targeting Cyclin B1 are essential tools for studying cell cycle dynamics, protein localization, and expression levels in both normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Specificity and validation are crucial, as cross-reactivity with other cyclin family members (e.g., Cyclin B2) must be ruled out. High-quality Cyclin B1 antibodies typically recognize epitopes within its conserved N-terminal or C-terminal regions and can detect endogenous proteins across species, including human, mouse, and rat. Researchers also utilize these antibodies to investigate Cyclin B1’s subcellular shuttling (nuclear-cytoplasmic transport) and phosphorylation status, which regulate its activity during mitotic progression. In cancer research, they help correlate Cyclin B1 expression with clinical outcomes, such as tumor grade or drug resistance.
×
